AI-Crafted diet supplement takes on type 2 diabetes
NCT ID NCT07622628
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether a special nutritional supplement, designed using artificial intelligence, can help adults with type 2 diabetes lower their blood sugar over 24 weeks. One hundred participants will receive either the active supplement or a placebo, alongside their usual diabetes care. The main goal is to see if the supplement leads to a greater drop in HbA1c, a key blood sugar marker.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bakırçay University Faculty of Medicine Endocrinology Department
RECRUITINGIzmir, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
microbiome-targeted oral food supplement
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage blood sugar in type 2 diabetes.
What could go wrong
This is a small early proof-of-concept study with only 100 participants, so results may not be conclusive or generalizable. The supplement is fixed and not personalized during the trial.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.